Drug intelligence / Profile preview

Allogeneic cytokine-induced killer cells (Singapore General Hospital)

Development stage: Unknown
Lead developer: Singapore General Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Allogeneic cytokine-induced killer (CIK) cells are an ex vivo expanded cell-based immunotherapy developed by Singapore General Hospital for the treatment of hematological malignancies relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). These cells are generated from donor peripheral blood mononuclear cells through sequential stimulation with interferon-gamma (IFN-γ), anti-CD3 monoclonal antibodies, and interleukin-2 (IL-2). This process results in a heterogeneous cell population dominated by CD3+CD56+ T cells that possess natural killer (NK)-like functional properties. Unlike conventional T cells, CIK cells exert potent antineoplastic activity in a major histocompatibility complex (MHC)-unrestricted manner, primarily mediated by the engagement of the natural killer group 2 member D (NKG2D) receptor with its ligands on malignant cells. This therapy aims to enhance the graft-versus-leukemia (GVL) effect while minimizing the risk of graft-versus-host disease (GVHD) compared to standard donor lymphocyte infusions (DLI).

Other names: Cytokine-induced killer cellsCIK cell immunotherapy

Targets

MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on Allogeneic cytokine-induced killer cells (Singapore General Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allogeneic cytokine-induced killer cells (Singapore General Hospital).

Explore the full profile